Last checked at 3 May 2017 14:15
3 May 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Publication of Annual Report and Notification of AGM
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), gives notice that its Annual Report and Accounts for the year ended 31 December 2016 ("Annual Report & Accounts 2016") has been published on the "Annual & Interim Reports" section of the Company's website at www.deltexmedical.com.
The Company announced a summary of its results on 27 April 2017 and expects to post printed copies of the Annual Report & Accounts 2016 on 5 May 2017 to shareholders who have informed the Company of their wish to receive reports of this nature in hard copy.
Deltex Medical also announces that its Annual General Meeting will be held at 11:00am on 9 June 2017 at the offices of Laytons Solicitors LLP, 2 More London Riverside, London, SE1 2AP. The formal notice and resolutions can be found at the back of the Annual Report & Accounts 2016. The related proxy card will be posted on 5 May 2017 to shareholders on the register on 26 April 2017.
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director
| |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Financial Public Relations | |
IFC Advisory Ltd | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.